Therapeutic intervention strategies for Nipah virus infection: a scoping review

Closed

Ikhwan Yuda Kusuma, Bizhar Ahmed Tayeb, Muhammad Jayyid Zidan, Septi Nurkhasanah, Rian Nurahman, Ilil Maidatuz Zulfa

2026 Infectious Diseases Vol. 58 Issue 6 Review Cited by 1 Quartile

Abstract

Introduction: Nipah virus (NiV) infection, a zoonotic disease, has caused recurrent outbreaks in South and Southeast Asia, with case fatality rates ranging from 38% to 75%. The clinical management of NiV disease (NiVD) relies on supportive care, with unapproved antiviral therapies and no licensed vaccines currently available. Objectives: This scoping review aims to synthesise and map the available evidence on therapeutic strategies for NiV infection. Methods: A systematic search was conducted in PubMed and Scopus for studies published from 1 January 1999 to 1 February 2026, focusing on clinical studies, animal experiments, in vitro investigations and in silico analyses evaluating NiV therapies. Eligible studies were selected based on their population or experimental model, therapeutic intervention, evaluation methods, efficacy outcomes, safety findings and proposed molecular mechanisms. Results: Of 1703 articles screened, 16 studies were included, covering clinical reports, animal models, in vitro experiments and in silico analyses. Therapeutic interventions evaluated included antivirals (ribavirin, favipiravir, remdesivir and RdRp-targeted candidates), passive immunotherapy (monoclonal antibodies targeting viral glycoproteins) and computationally prioritised compounds (e.g. phytochemicals, bioisosteres and repurposed drugs). Most interventions targeted viral entry, RNA replication or multiple stages of the NiV life cycle. However, a substantial gap exists between the urgent clinical need for effective treatments and the limited availability of clinically validated therapies. Conclusion: Effective, clinically validated therapies for NiV infection are still lacking. Translational research, outbreak-ready clinical trial frameworks and prioritisation of promising therapeutic candidates are crucial for improving preparedness and clinical outcomes in future NiV outbreaks. © 2026 Society for Scandinavian Journal of Infectious Diseases.

Affiliations

Pharmacy Study Program, Faculty of Health, Universitas Harapan Bangsa, Purwokerto, Indonesia; Molecular Microbiology, New-standard Laboratories, Duhok, Iraq; Research Department of Practise and Policy, University College London, London, United Kingdom

Research at a Glance

Premium content — register to unlock

Research at a Glance

Register to unlock

Topics & SDG Alignment

Premium content — register to unlock

Topics & SDG Alignment

Register to unlock

Collaboration

Premium content — register to unlock

Collaboration

Register to unlock

Author Profile (Selected)

Premium content — register to unlock

Author Profile (Selected)

Register to unlock

References Overview

Premium content — register to unlock

References Overview

Register to unlock

Journal & Source

Premium content — register to unlock

Journal & Source

Register to unlock

Metadata & Integrity

Premium content — register to unlock

Metadata & Integrity

Register to unlock